Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2

Status

Terminated 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Breast 1

Conditions

Breast Neoplasms 9Colorectal Neoplasms 2Brain Neoplasms 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Neoplasm Metastasis 1HER2-positive Breast Cancer 1Esophageal Neoplasms 1Endometrial Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Temozolomide 26Bevacizumab 14Radiosurgery 12Radiotherapy 9pembrolizumab 8Carboplatin 8Trastuzumab 6temsirolimus 5Sirolimus 5Erlotinib Hydrochloride 5abemaciclib 4Paclitaxel 4Irinotecan 4Capecitabine 4tipifarnib 3Sorafenib 3Radiation 3Mental Status and Dementia Tests 3Ipilimumab 3Everolimus 3Aminolevulinic Acid 3130-nm albumin-bound paclitaxel 3tucatinib 2pertuzumab 2fludarabine 2durvalumab 2alovudine 2alectinib 2Vorinostat 2Surgical Procedures, Operative 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Brain Neoplasms × Ado-Trastuzumab Emtansine × Clear all
NCT05593094 2026-05-26

A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors

Hoffmann-La Roche

Phase 1/2 Active not recruiting
210 enrolled
CNS

Brain Neoplasms

NCT03190967 2023-10-11

T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
12 enrolled 16 charts
BreastCNS

Brain Neoplasms, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡